October 26, 2020 Regulatory LIDDS’ NanoZolid-TLR9 agonist demonstrates strong and durable preclinical anti-tumoral effect
August 20, 2020 Regulatory LIDDS licensee, Puheng Pharma, evaluates a novel expeditated regulatory path for Liproca Depot in China
June 11, 2020 Regulatory LIDDS announces a capital raise of a total of approximately SEK 59.3 million and accordingly secures long-term financing
May 19, 2020 Regulatory Correction of press release: Liproca Phase IIb study results indicate cancer control
May 18, 2020 Regulatory LIDDS announces positive meeting with the Swedish Medical Products Agency, confirming the Liproca® Depot Phase III study design
March 25, 2020 Regulatory LIDDS announces positive preclinical data for NanoZolid®-TLR9 agonist project
February 11, 2020 Regulatory LIDDS: Last patient treated in Liproca® Depot open label extension study
January 9, 2020 Regulatory LIDDS obtains novel US product patent that significantly broadens protection on NanoZolid® pharmaceuticals